You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Bayer Hlthcare Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Bayer Hlthcare
International Patents:776
US Patents:38
Tradenames:57
Ingredients:37
NDAs:56

Drugs and US Patents for Bayer Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare ULTRAVIST 370 iopromide INJECTABLE;INJECTION 020220-001 May 10, 1995 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Bayer Hlthcare UROVIST CYSTO diatrizoate meglumine SOLUTION;URETERAL 087729-001 Sep 23, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-002 Oct 8, 2013 AB RX Yes No 11,203,593 ⤷  Try a Trial Y Y ⤷  Try a Trial
Bayer Hlthcare ASTEPRO ALLERGY azelastine hydrochloride SPRAY, METERED;NASAL 213872-001 Jun 17, 2021 OTC Yes Yes 9,919,050 ⤷  Try a Trial Y ⤷  Try a Trial
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 DISCN Yes No 8,613,950 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bayer Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare YAZ drospirenone; ethinyl estradiol TABLET;ORAL 021676-001 Mar 16, 2006 RE38253 ⤷  Try a Trial
Bayer Hlthcare BEYAZ drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022532-001 Sep 24, 2010 RE37564 ⤷  Try a Trial
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-003 Aug 19, 2003 8,841,446 ⤷  Try a Trial
Bayer Hlthcare ULTRAVIST (PHARMACY BULK) iopromide INJECTABLE;INJECTION 021425-003 Mar 12, 2004 4,364,921 ⤷  Try a Trial
Bayer Hlthcare YASMIN drospirenone; ethinyl estradiol TABLET;ORAL-28 021098-001 May 11, 2001 6,787,531 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAYER HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28

Supplementary Protection Certificates for Bayer Hlthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0398460 12/2004 Austria ⤷  Try a Trial PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
1453521 C201630040 Spain ⤷  Try a Trial PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211
3106463 2090009-8 Sweden ⤷  Try a Trial PRODUCT NAME: LAROTRECTINIB,OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REG. NO/DATE: EU/1/19/1385 20190923
1663978 SPC/GB13/076 United Kingdom ⤷  Try a Trial PRODUCT NAME: REGORAFENIB AND ITS SALTS; REGISTERED: UK EU/1/13/858/001 20130829; UK EU/1/13/858/002 20130829
3106463 20C1012 France ⤷  Try a Trial PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER UN SULFATE DE LAROTRECTINIB TEL QUE L'HYDROGENOSULFATE DE LAROTRECTINIB; NAT. REGISTRATION NO/DATE: EU/1/19/1385 20190923; FIRST REGISTRATION: DE - EU/1/19/1385 20190923
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.